Nature Medicine, Published online: 08 November 2026; doi:10.1038/s41591-026-04762-3
As presented at the 2026 American Heart Association Scientific Sessions, in a placebo-controlled randomized clinical trial, semaglutide significantly improved pulmonary artery wedge pressure and other hemodynamic parameters during low-intensity exercise in individuals with heart failure with preserved ejection fraction and obesity.
